| 收盘价格 | 14.49 |
| 成交量 | 2,744 |
| 平均成交量 (3个月) | 1,129,665 |
| 市值 | 928,205,696 |
| 市盈率 (P/E TTM) | 10.24 |
| 预期市盈率 (P/E Forward) | 10.10 |
| 价格/销量 (P/S) | 2.59 |
| 股市价格/股市净资产 (P/B) | 1.36 |
| 52周波幅 | |
| 利润日期 | 6 May 2026 |
| 营业毛利率 | 44.79% |
| 营业利益率 (TTM) | 20.06% |
| 稀释每股收益 (EPS TTM) | 2.23 |
| 季度收入增长率 (YOY) | -3.00% |
| 季度盈利增长率 (YOY) | -23.20% |
| 总债务/股东权益 (D/E MRQ) | 0.90% |
| 流动比率 (MRQ) | 8.73 |
| 营业现金流 (OCF TTM) | 122.59 M |
| 杠杆自由现金流 (LFCF TTM) | 73.58 M |
| 资产报酬率 (ROA TTM) | 8.62% |
| 股东权益报酬率 (ROE TTM) | 24.50% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Devices (US) | 混合的 | 看跌 |
| Medical Devices (全球的) | 混合的 | 看跌 | |
| 股票 | InMode Ltd. | 混合的 | 看跌 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | -0.83 |
|
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, among others. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia, Israel, and other regions. |
|
| 部门 | Healthcare |
| 行业 | Medical Devices |
| 投资方式 | Small Value |
| 内部持股比例 | 15.35% |
| 机构持股比例 | 72.07% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| North Growth Management Ltd. | 31 Dec 2025 | 662,000 |
该时间范围内无数据。
该时间范围内无数据。
| 日期 | 类型 | 细节 |
|---|---|---|
| 03 Feb 2026 | 公告 | InMode to Participate in the 13th Annual BTIG MedTech, Digital Health, Life Sciences & Diagnostics Tools Conference |
| 02 Feb 2026 | 公告 | InMode Responds to Transaction Rumors |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合